
Alveus Therapeutics Raises $160M
By Jeremy Martin • January 21, 2026

In a significant win for Black-led innovation in biotech/health-tech, Alveus Therapeutics (highlighted in recent "Black Innovation" roundups) has exited stealth mode with a massive $160 million in funding.The company is developing alternatives to popular weight-loss drugs like Ozempic, positioning itself as a major player in the life sciences sector for 2026.
- The Scoop: In a massive win for biotech, Alveus Therapeutics launched with $160 million in Series A funding on January 8. They are developing next-gen oral drugs for obesity and metabolic disease that could rival Ozempic.
- Impact on Black Culture & Community: This is a dual-impact story. Economically, it showcases Black leadership in the high-stakes world of biotech venture capital. Culturally, it addresses a health equity crisis; metabolic diseases disproportionately affect Black communities due to systemic food apartheid. A Black-led company solving this issue implies a solution that might prioritize accessibility and trust in medical systems where it has historically been lacking.
Never miss out on money moves again!
Sign up to get industry insights, trends, and more in your inbox.
Contact Us
Thank you for contacting us.
We will get back to you as soon as possible.
We will get back to you as soon as possible.
Oops, there was an error sending your message.
Please try again later.
Please try again later.
SHARE THIS
Featured
Latest Posts
By Jeremy Martin
•
May 5, 2026
Step into the gritty, unfiltered battleground where the rules are thrown out the window, respect is earned the hard way, and the action never stops. GM Dante Crossland has promised a show that will shake the very foundation of the URF, but in this universe, absolutely nothing goes exactly as planned.






